Trial Profile
A Phase IV, Real World Observational Study On The Use Of Akynzeo® (Netupitant/Palonosetron) For The Prevention Of Nausea and Vomiting in Oncology Patients Receiving Highly Emetogenic Chemotherapy (HEC) Over Multiple Cycles
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms EVOLVE_CINV
- Sponsors Purdue Pharma
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.